All In Biotech

Drug Trial Radar · NCT04562090

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

A Phase 4, Open-label, Randomized, Prospective, Interventional Post-authorization Efficacy and Safety Study of Mirabegron 50 mg and 25 mg for the Treatment of Overactive Bladder in Chinese Subjects

Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

249

Actual

Start

Jan 6, 2021

Primary completion

Mar 17, 2022

Study completion Mar 30, 2022

Sponsor

Lead sponsor
Astellas Pharma China, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Sep 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants. This study also evaluated the safety of mirabegron for the treatment of OAB in Chinese participants, evaluated other efficacy variables of mirabegron for the treatment of OAB and explored different mirabegron starting doses.

Conditions

  • Urge Incontinence
  • Overactive Bladder (OAB)

Interventions

  • mirabegronDrug

    Mirabegron was administered as single oral dose of 25 mg or 50 mg sustained-release tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg GroupTime frame: Baseline, week 12

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site CN86001

    Beijing, China

  • Site CN86004

    Beijing, China

  • Site CN86014

    Beijing, China

  • Site CN86010

    Chengdu, China

  • Site CN86009

    Guangzhou, China

  • Site CN86018

    Guangzhou, China

  • Site CN86003

    Lanzhou, China

  • Site CN86013

    Shanghai, China

  • Site CN86002

    Suzhou, China

  • Site CN86021

    Taiyuan, China

  • Site CN86011

    Wuhan, China

  • Site CN86022

    Wuxi, China

  • Site CN86012

    Xi'an, China

  • Site CN86007

    Zhengzhou, China

  • Site CN86020

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.